Amlodipine interest in HRT (Hormone Replacement Therapy) cycle for frozen embryo transfer in the uterine pulsatility indices correction: double-blind randomized controlled trial - AmlodIP

niversity hospital of Montpellier0 个研究点目标入组 70 人开始时间: 2021年4月6日最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•Female patient ,
•Patient scheduled for a blastocyst-type frozen embryo transfer (vitrification on D5) on cycle with hormone replacement therapy.
•Measurement of the two uterine PIs greater than 3 (>) during the first monitoring at Dm (corresponding to D13-D16 of the cycle).
•18 years (=) age (=) 38 years.
•BMI = 30 kg / m2.
•Carrying out a transfer test qualified as easy (passage of the cervix with a flexible or rigid catheter, without anesthesia or Pozzi forceps).
•Collection and signature of free and informed consent.
•Affiliation or beneficiary of a health insurance plan.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 70
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•The patient actively smokes tobacco (at least one cigarette per day at the time of inclusion in the study).
•The patient is receiving oocytes.
•A preimplantation diagnosis is planned for this patient.
•The patient has stage 3 or 4 endometriosis, or adenomyosis.
•The patient has a contraindication to the use of amlodipine (recent myocardial infarction of less than one month, severe angina pectoris, severe hepatic impairment, taking ciclosporin, low blood pressure, hypersensitivity to amlodipine, dihydropyridine derivatives).
•Concomitant intake of CYP3A4 inhibitors or enzyme inducers
•The patient is already being treated for high blood pressure.
•The patient has a recruited ovarian follicle (> 12mm) during the first monitoring (the most conservative case).
•The patient is participating in another interventional study on the human person.
•The patient is in an exclusion period determined by a previous study.
•The patient has already participated in this study.
•The patient is under the protection of justice, under guardianship or curatorship.
•It is impossible to give the patient informed information.
•It turns out to be impossible to carry out monitoring with an experienced sonographer.
•Lactating patient according to article L1121-5 of the CSP
•Patient protected or unable to give consent according to article L1121-8 of the Public Health Code (CSP).
•Vulnerable person according to article L1121-6 of the CSP.

发起方

niversity hospital of Montpellier